Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia

24 Sept 2019

Abstract excerpt

Not all chronic myeloid leukemia (CML) patients are cured with tyrosine kinase inhibitors (TKIs), and a proportion of them develop resistance. Recently, continuous BCR-ABL gene expression has been found in resistant cells with undetectable BCR-ABL protein expression, indicating that resistance may occur through kinase independent mechanisms, mainly due to the persistence of leukemia stem cells (LSCs). LSCs reside...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31612105
DOI: 10.3389/fonc.2019.00939

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaPMID 31612105Read ↗

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateSemantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Resistance in chronic myeloid leukemia: definitions and novel therapeutic agentsSemantic proximity Read ↗

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read ↗

Molecular biology of bcr-abl1–positive chronic myeloid leukemiaSemantic proximity Read ↗

Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Resistance to Imatinib: Mechanisms and ManagementSemantic proximity Read ↗

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.Semantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.